Literature DB >> 18267276

SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.

Jan Booij1, Remco J J Knol.   

Abstract

In studies on (premotor) Parkinson's disease (PD), single photon emission computed tomography (SPECT) studies have focused on imaging of the presynaptic dopamine transporter (DAT) and postsynaptic dopamine D2 receptors (D2Rs). Here we review the results of SPECT studies on the dopaminergic system in PD, with particular emphasis on: the accuracy of SPECT imaging of the dopaminergic system to detect alternations of the dopaminergic system in early PD, the diagnostic accuracy of DAT SPECT in PD, the contribution of DAT imaging to detect preclinical phases of PD, and the potential role of SPECT imaging to monitoring progression of dopaminergic degeneration in PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18267276     DOI: 10.1016/S1353-8020(08)70042-7

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  15 in total

1.  Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.

Authors:  Lior Greenbaum; Robert C Smith; Mordechai Lorberboym; Anna Alkelai; Polina Zozulinsky; Tzuri Lifschytz; Tzuri Lifshytz; Yoav Kohn; Ruth Djaldetti; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

2.  EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

Authors:  Koen Van Laere; Andrea Varrone; Jan Booij; Thierry Vander Borght; Flavio Nobili; Ozlem L Kapucu; Zuzana Walker; Kjell Någren; Klaus Tatsch; Jacques Darcourt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

3.  Utility of 123I-FP-CIT SPECT for dementia diagnoses and therapeutic strategies in elderly patients.

Authors:  Z Barrou; J Boddaert; V Faucounau; M O Habert; S Greffard; B Dieudonné; M Verny
Journal:  J Nutr Health Aging       Date:  2014-01       Impact factor: 4.075

4.  Variability of presynaptic nigrostriatal dopaminergic function and clinical heterogeneity in a dopa-responsive dystonia family with GCH-1 gene mutation.

Authors:  Juei-Jueng Lin; Chin-Song Lu; Chon-Haw Tsai
Journal:  J Neurol       Date:  2017-12-30       Impact factor: 4.849

5.  Trace amine-associated receptor 1 as a monoaminergic modulator in brain.

Authors:  Zhihua Xie; Gregory M Miller
Journal:  Biochem Pharmacol       Date:  2009-05-29       Impact factor: 5.858

6.  Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism.

Authors:  Susanna Jakobson Mo; Jan Linder; Lars Forsgren; Katrine Riklund
Journal:  Mov Disord Clin Pract       Date:  2014-09-30

7.  MIBG Myocardial Scintigraphy Identifies Premotor PD/DLB During a Negative DAT Scan Period: Second Report.

Authors:  Ryuji Sakakibara; Fuyuki Tateno; Yosuke Aiba; Tsuyoshi Ogata; Masahiko Kishi; Hitoshi Terada; Tsutomu Inaoka; Tomoya Nakatsuka; Katsuyoshi Matsuoka
Journal:  Mov Disord Clin Pract       Date:  2018-11-09

Review 8.  Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.

Authors:  Lior Greenbaum; Bernard Lerer
Journal:  Front Neurol       Date:  2015-02-20       Impact factor: 4.003

9.  Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.

Authors:  Adamantios Mamais; Meera Raja; Claudia Manzoni; Sybille Dihanich; Andrew Lees; Darren Moore; Patrick A Lewis; Rina Bandopadhyay
Journal:  Neurobiol Dis       Date:  2013-06-05       Impact factor: 5.996

10.  Network structure of brain atrophy in de novo Parkinson's disease.

Authors:  Yashar Zeighami; Miguel Ulla; Yasser Iturria-Medina; Mahsa Dadar; Yu Zhang; Kevin Michel-Herve Larcher; Vladimir Fonov; Alan C Evans; D Louis Collins; Alain Dagher
Journal:  Elife       Date:  2015-09-07       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.